Latest Cardiology News

Page 1 of 4
The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.
Logan Eniac
Logan Eniac
14 Feb 2026
Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.
Logan Eniac
Logan Eniac
14 Feb 2026
Pro Medicus has reported its strongest half-year performance yet, with revenue and profits surging alongside a wave of new multi-million dollar contracts and strategic AI investments. The healthcare IT leader is expanding its global footprint and cloud capabilities, setting the stage for sustained growth.
Ada Torres
Ada Torres
12 Feb 2026
Pro Medicus Limited reported a robust half-year performance, with underlying profit after tax rising by approximately 30%, driven by significant new sales and strategic implementations. The company remains confident in its proprietary technology's resilience against AI disruption while expanding its market footprint.
Victor Sage
Victor Sage
12 Feb 2026
Pro Medicus Limited has reported a stellar half-year performance with revenue up 28.4% and a surge in net profit, driven by major US contract wins and strategic investments.
Ada Torres
Ada Torres
12 Feb 2026
A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.
Logan Eniac
Logan Eniac
7 Feb 2026
Imricor Medical Systems has welcomed Oklahoma Heart Institute as the fourth U.S. site in its pivotal VISABL-AFL clinical trial, accelerating patient recruitment and the FDA approval pathway for its MRI-guided cardiac ablation technology.
Ada Torres
Ada Torres
3 Feb 2026
CONNEQT Health has reported a remarkable surge in Pulse device sales, exceeding 200% growth quarter-on-quarter, while advancing its transition to a recurring revenue model through enterprise contracts and consumer subscriptions.
Ada Torres
Ada Torres
30 Jan 2026
Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.
Ada Torres
Ada Torres
23 Jan 2026
Imricor Medical Systems has secured Virginia Commonwealth University Health as the third US site for its VISABL-AFL clinical trial, advancing its FDA approval pathway for MRI-guided cardiac ablation technology.
Ada Torres
Ada Torres
21 Jan 2026
Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.
Ada Torres
Ada Torres
15 Dec 2025
Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.
Ada Torres
Ada Torres
15 Dec 2025